Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2009-01-28
2010-12-28
Weber, Jon P (Department: 1657)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094200
Reexamination Certificate
active
07858085
ABSTRACT:
The present invention provides methods for using human placental alkaline phosphatase or an active derivative to reduce blood glucose level in a mammal. Treatment regimens provided by the invention may be used to control Type 1 and Type 2 forms of diabetes in humans. The methods and treatment regimens may be effective to maintain the human's blood glucose level below about 10 mM, and preferably within the normal range of 4 mM to 7 mM. The methods and treatment regimens may be used in combination with administration of known anti-diabetic medicaments. Also provided by the invention is a method for inducing weight loss or reducing an expected weight gain caused by or associated with obesity or Type 2 diabetes. The invention further provides a preparation for administration to a human, the preparation comprising homogeneous purified human placental alkaline phosphatase in a physiologically acceptable carrier.
REFERENCES:
patent: 4030995 (1977-06-01), Starkweather
patent: 4306020 (1981-12-01), Meiattini
patent: 6290952 (2001-09-01), Poelstra et al.
patent: 6623947 (2003-09-01), Chen
patent: 7011965 (2006-03-01), Kiss
patent: 7014852 (2006-03-01), Kiss
patent: 7048914 (2006-05-01), Kiss
patent: WO 97/47316 (1997-12-01), None
patent: WO 02/072136 (2002-09-01), None
Anthony et al., “Signaling Pathways Involved in Translational control of Protein Synthesis in skeletal Muscle by Leucine,” Symposium: Leucine as a Nutritional Signal, pp. 856S-860S, San Diego, CA, 2001.
Atkinson, “Thirty Years of Investigating the Autoimmune Basis for Type 1 Diabetes,” ADA Outstanding Scientific Achievement Lecture 2004, 2005.
B.M. Spiegelman and J.S. Flier, “Obesity and the regulation of energy balance.” Cell 104, 531-543 (2001).
Baracos, “Management of Muscle Wasting in Cancer-Assoicated Cachexia,” Cancer-Related Fatigue: New Directions for Research, vol. 192, pp. 1669-16677, 2001.
Barbieri et al., “Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons,” Am J Physiol Endocrinol Metab, vol. 284, pp. E481-E487, 2003.
Barton-Davis et al., “Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function,” Proc. Natl. Acad. Sci. USA, vol. 95, pp. 15603-15607, 1998.
Beck et al., “Expression of Human Placental alkaline Phosphatase inEscherichia coli,” Protein Expression and Purification, vol. 5, pp. 192-197, 1994.
Bell, G.I. and Polonsky, K.S., “Diabetes mellitus and genetically programmed defects in .beta.-cell function.” Nature 414, 788-791 (2001).
Bonifacio, E., Atkinson, M., Eisenbarth, G., Serreze, D., Kay, T.W.H., Lee-Chan, E. and Singh, B., “International Workshop on lessons from animal models for human type 1 diabetes: Identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice.” Diabetes 50, 2451-2458 (2001).
Bottino et al., “Preservation of Human Islet Cell Functional Mass by Anti-Oxidative Action of a Novel SOD Mimic Compound,” Diabetes, vol. 51, pp. 2561-2567, 2002.
Bottino et al., “Response of Human Islets to Isolation Stress and the Effect of Antioxidant Treatment,” Diabetes, vol. 53, pp. 2559-2568, 2004.
Brandhorst et al., “Successful Human Islet Isolation Utilizing Recombinant Collagenase,” Diabetes, vol. 52, pp. 1143-1146, 2003.
Brock et al., “Measurement of placental alkaline phosphatase in maternal plasma as an indicator of subsequent low birthweight outcome”, British Journal of Obstetrics and Gynacology, Jan. 1988, vol. 95, pp. 769-783.
Brownlee, “The Pathobiology of Diabetic Complications,” Banting Lecture 2004, 2005.
Brownlee, M., “Biochemistry and molecular cell biology of diabetic complications.” Nature 414, 813 (2001).
Butler et al., “.beta.-cell Deficit and Increased .beta.-cell Apoptosis in Humans With Type 2 Diabetes”, Diabetes, 2003, pp. 102-110, vol. 52.
Cao et al., “Pancreatic-Derived Factor (FAM3B), a Novel Islet Cytokine, Induces Apoptosis of Insulin-Secreting .beta.-cells”, Diabetes, Sep. 2003, pp. 2296-2303, vol. 52, American Diabetes Association.
Carlevaro et al., “Transferrin Promotes Endothelial Cell Migration and Invasion: Implication in Cartilage Neovascularization,” The Journal of Cell Biology, vol. 136, No. 6, pp. 1375-1384, 1997.
Carmichael et al., “Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing,” Cancer Research, vol. 47, pp. 936-942, 1987.
Carroll et al. “Combined growth hormone/insulin-like growth factor I in addition to glutamine-supplemented TPN results in net protein anabolism in critical illness,” Am J Physiol Endocrinol Metab, vol. 286, pp. E151-E157, 2004.
Cebrian et al., “Overexpression o f Parathyroid Hormone-Related Protein Inhibits Pancreatic .beta.-Cell Death in Vivo and In Vitro,” Diabetes, vol. 51, pp. 3003-3013, 2002.
Chang et al., “Aging and insulin secretion”, Am J Physiol Endocrinol Metab, Jan. 2003, pp. E7-E12, vol. 284, the American Physiological Society.
Chang, G.-G., Shiao, M.-S., Lee, K.-R. and Wu, J.-J., “Modification of human placental alkaline phosphatase by periodate-oxidized 1,N. sup.6-ethenoadenosine monophosphate.” Biochem. J. 272, 683-690 (1990).
Chang, T.-C., Huang, S.-M., Huang, T.-M. and Chang, G.-G., “Human Placenta alkaline phosphatase: An improved purification procedure and kinetic studies.” Eur. J. Biochem. 209, 241-247 (1992).
Chen et al., “Overespression of Metallothionein in Pancreatic .beta.-Cells Reduces Streptozotocin-Induced DNA Damage and Diabetes,” Diabetes, vol. 50, pp. 2040-2046, 2001.
Clubb, J.S., Neale, F.C. and Posen, S., “The behavior of infused human placental alkaline phosphatase in human subjects.” J. Lab. & Clin. Med. 66, 493-507 (1965).
De Arcangelis et al., “IGF-induced Differentiation of L6 Myogenic Cells Requires the Activity of cAMP-Phosphodiesterase,” Molecular Biology of the Cell, vol. 14, pp. 1392-1404, 2003.
De Benedetti et al., “Interleukin 6 Causes Growth Impairment in Transgenic Mice through a Decrease in Insulin-like Growth Factor-I,” J. Clin. Invest. vol. 99, pp. 643-650, 1997.
De Leon et al., “Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy,” Diabetes, vol. 52, pp. 365-371, 2003.
Eitel et al., “Different role of saturated and unsaturated fatty acids in .beta.-cell apoptosis,” Biochemical and Biophysical Research Communications, vol. 299, pp. 853-856, 2002.
Eitel et al., “Protein Kinase C.delta. Activation and Translocation to the Nucleus Are Required for Fatty Acid-Induced Apoptosis of Insulin-Secreting Cells,” Diabetes, vol. 52, pp. 991-997 2003.
Ekblom et al., “Transferrin as a fetal growth factor: Acquisition of responsiveness related to embryonic induction,” Proc. Natl. Acad. Sci. USA, vol. 80, pp. 2651-2655, 1983.
F.M. Gregoire, “Adipocyte differentiation: From fibroblast to endocrine cell.” Exp. Biol. Med. 226, 997-2001 (2001).
Farris et al., “Insulin-degrading enzyme regulates the levels of insulin, amyloid .beta.-protein, and the .beta.-amyloid precursor protein intracellular domain in vivo”, Proc. Natl. Acad. Sci., Apr. 1, 2003, pp. 4162-4167, vol. 100, No. 7.
Ferrando et al., “Testosterone administration to older men improves muscle function: molecular and physiolological mechanisms,” Am J Physiol Endocrinol Metab, vol. 282, pp. E601-E607, 2002.
Ferrannini et al., “.beta.-cell Function in Obesity”, Diabetes, Dec. 2004, pp. S26-S33, vol. 53, Supplement 3, American Diabetes Association.
Green et al., “CD4.sup.+ CD25.sup.+ T regulatory cells control anti-islet CD8.sup.+ T cells through TGF-.beta.—TGF
Faegre & Benson LLP
Singh Satyendra K
Weber Jon P
Zoltan Laboratories LLC
LandOfFree
Alkaline phosphatase to control diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alkaline phosphatase to control diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alkaline phosphatase to control diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150021